SVRA · Savara, Inc.
$4.52
+7.11% last session
End-of-day data · close of 2026-10-26
Market cap
$1B
Enterprise value
$1B
Trailing P/E
—
Forward P/E
-12.3
Dividend yield
0.0%
Beta
0.20
Avg volume
2M
Employees
0K
Daily Change %
7.11%
5 Days Change
-0.44%
10 Days Change
1.57%
30 Days Change
-9.60%
60 Days Change
-14.07%
Month to Day Change
-10.41%
Year to Day Change
-25.04%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — SVRA
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-07
Latest call per bank · past 12 months
JP Morgan
Overweight$12.00
+165.5% vs priceWells Fargo
Overweight$9.00
+99.1% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-07 | JP Morgan | Initiates | Overweight | $0.00 → $12.00 |
| 2025-12-23 | HC Wainwright & Co. | Maintains | Buy | $8.00 → $10.00 |
| 2025-12-18 | Wells Fargo | Maintains | Overweight | $7.00 → $9.00 |
| 2025-11-14 | Oppenheimer | Maintains | Outperform | $8.00 → $9.00 |
| 2025-11-13 | Citizens | Maintains | Market Outperform | $11.00 → $10.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-26
- neutral: RSI (14): RSI is 42 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 11.7% below the 50-day MA ($5.12).
- bearish: Price vs 200-day MA: Trading 16.4% below the 200-day MA ($5.41).
- bearish: MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- bearish: MACD (12,26,9): MACD histogram is negative (-0.02) — short-term momentum is fading.
- neutral: 52-week range: Price sits between the 52-week low ($3.95) and high ($6.94).
SVRA Price Chart
Loading chart for SVRA…
Fundamentals
About Savara, Inc.
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Yardley, Pennsylvania.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$131B 14.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 5.0% YTD
MRNA
Moderna, Inc.
$79B 574.3% YTD
ARGX
argenx SE
$55B 3.4% YTD
ONC
BeOne Medicines Ltd.
$42B 22.1% YTD
RVMD
Revolution Medicines, Inc.
$39B 130.9% YTD
RPRX
Royalty Pharma plc
$37B 69.9% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.